MedTrace Logo

Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation

NCT02942407 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 154

Last updated 2020-12-29

Study results available
· View outcomes & findings →

Summary

This is a prospective, randomized, open-label, blinded end-point evaluation trial. The patient population consists of patients on hemodialysis who have atrial fibrillation (AF) and end-stage renal disease (ESRD) .

Conditions

Interventions

DRUG

apixaban

oral anticoagulant

DRUG

warfarin

oral anticoagulant

Sponsors & Collaborators

Principal Investigators

  • Christopher Granger, MD · Duke University

  • Glenn Chertow, MD · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2019-07-27
Completion
2019-08-12

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02942407 on ClinicalTrials.gov